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Abstract 
Gap junctions enable metabolic and electrical coupling of adjacent cells. Connexin 
36 (Cx36) is a gap junction protein found predominantly in mammalian neurons. 
Because Cx36 is expressed in many areas involved in the regulation of food intake, 
its role in this was explored. I therefore investigated whether genetic knockout 
(KO) of Cx36 affects the intake of various sweet tastants during long-term 
concurrent feeding with bland chow, and affects intake of sweet tastants alone 
during short-term feeding. In addition, I investigated whether a conditioned taste 
aversion (CTA) would be altered by KO of Cx36. LiCl was injected 
intraperitoneally (IP) following exposure to a sweet novel tastant. 48 hours later 
mice were given a two-bottle preference test of tastant vs. water to determine 
aversive response. Cx36 KO animals consumed less sweet palatable tastants and 
consumed more bland chow during long-term intake. Sweet tastant consumption 
was similarly increased during short-term intake. This is suggestive of Cx36 being 
implicated in both reward mediated and homeostatic regulation. A CTA was 
enhanced by the KO of Cx36, potentially due to its role in the reward system, 
and/or an effect of hypothalamic endocrine nuclei implicated in the acquisition of 
a CTA. In summary, Cx36 may be involved in reward system response to sweet 
palatable food consumption, and the magnitude of aversive response. Cx36 may 
also be implicated in post-ingestive endocrine food intake and aversion regulation. 
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1. Introduction 
1.1 Gap Junctions 
Gap junctions are permeable channels established between adjacent cells that 
enable metabolic and electrical coupling. They are created when a hexameric 
connexon structure of connexin proteins on one cell docks to another connexon 
hemichannel on a neighbouring cell1,2. The formed channel allows exchange of 
small hydrophilic molecules up to 1kD such as ions and secondary messengers2. 
Gap junctions are crucial for cells located distantly from blood vessels, the shared 
cytoplasm means cell nourishment can be facilitated cell to adjacent cell. 
Conversely, gap junctions can uncouple to protect healthy cells by isolating them 
from dysfunctional cells3. The ionic permeability of gap junctions allows 
propagation of electrical signals to gap junction connected cells. Gap junctions are 
found throughout the vertebrate body in most tissues such as the CNS, 
reproductive organs, retina, liver, kidney, and even in bone1,4. A specialized role 
for each connexin is suspected as they show tissue specific expression, despite 
most tissues expressing at least two connexins5. 
There are a number of tissues such as the heart and brain that require much faster 
electrical signal transmission than allowed by synaptic chemical communication. 
This requirement is met by membrane-bound gap junctions allowing for ultra-fast 
intercellular transmission between cells in immediate proximity to each other, 
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bypassing the need to send chemicals extracellularly6. In addition to increased 
speed of signal transmission, gap junctions give the ability for the synchronization 
and co-ordination of groups of cells7,8.  
Evidence of this is shown by the heart which requires a coordinated rhythmic 
contraction. Cardiomyocytes require action potential synchrony and coordinated 
contraction to maintain the correct function of the heart9. This propagation is 
possible because sodium ions can travel cell to cell through gap junctions located 
at intercalated discs10. There is evidence that a loss of synchrony or decreased gap 
junction conduction is implicated in arrhythmias and ventrical fibrillation11,12,13. 
Another example of an electrical synapse requirement is the role of gap junctions 
during parturition.  During pregnancy, gap junctions are not present in uterine 
myocardium smooth muscle; which may be a requirement for the maintenance of 
gestation14. Immediately prior to parturition, there is rapid formation of gap 
junction plaques in the myocardium. These plaques remain only throughout 
partruition and for a short time following15. As a result of this production of gap 
junctions, internal resistance of myometrial cells decreases, enhancing cell 
coupling which may be implicated in synchrony of uterine smooth muscle 
contractions during labour. Further, the formation of myometrial gap junctions 
may be hormonally controlled both locally and systemically. This has been shown 
to be modulated by estrogen and prostaglandin, and progesterone induced 
depression of gap junctions15,16,17. These examples illustrate the wide range of 
functions and variety of tissues gap junctions are an integral part of.  
 
1.2 Connexins 
Connexins are one of three gap junction protein families, and are found in 
chordates, whereas gap junction proteins from invertebrates are called innexins 
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and evolved independently as evidenced by the lack of amino acid homology18.  
Interestingly, all three families share strong structural similarities regardless of 
their evolutionary history19. There are however vertebrate proteins with amino 
acid homology to innexins, called panexins, though these are thought to rarely 
create gap junctions with other cells20. Pannexins may instead remain as hemi-
channels and mediate cell activity by releasing chemicals into the extracellular 
space between cells21. In mammals, genes have been found for 20-21 different 
connexins22,23. The nomenclature of each connexin is determined by its molecular 
size in kilodaltons (kD), and the abbreviation “Cx” for the name “connexin”, eg. 
Cx36 is 36 kD23.   
 
1.3 Structure 
These connexin proteins combine with 5 other connexins to construct hexamers 
called connexons. These connexon hemichannels then pair with another 
connexon on another cell, linking the two cytoplasms, with the gap junction 
bridging a 2nm space separating the cells22 (Fig. 1.1). This extracellular space was 
first visualized with the introduction of lanthanum which penetrated and 
differentiated the space in contrast to tight junctions which lanthanum could not 
pass through24,25,26.   
All connexins proteins are constructed of four a-helical transmembrane domains, 
a cytoplasmic loop, two extra-cellular loops, an N-terminal and C-terminal. The 
extracellular loops between M1 & M2 and M3 & M4 each contain three cystein 
residues which are important in creating the alignment of connexons when 
forming a gap junction2,27 (Fig. 1.2). The four transmembrane domains and the 
extracellular loops are well conserved allowing the formation of connexons 
constructed of differing connexins22. In contrast to the remainder of the connexin 
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protein; both the intracellular loop and primarily C-terminal have a variable 
sequence and length28, and these domains are targeted by a number of different 
proteins for post-translational modification29. It is these differences that 
predominantly determine the molecular differences between connexins and the 
differences in functionality and activity between connexons of various connexin 
compositions30. 
Connexons can be constructed with one type of connexin; called a homomeric 
connexon or with multiple connexin types; called a heteromeric connexon. This 
ability to combine different connexins is carried through to the entire gap junction 
itself, where two identical homomeric connexons from adjoining cells can dock to 
form a homotypic gap junction, or two differing connexons can dock to form 
heterotypic gap junctions22. There are only specific combinations of heterotypic 
junctions that can form, and the composition of gap junctions from various 
connexins subsequently alters their function by changing the permeability, ion 
selectivity, conductivity and metabolite selectivity30,31. 
 
Figure.1.1 A gap junction is an intercellular channel connecting cytoplasms of 
two cells. Each gap junction bridges a 2mm extracellular space and is constructed 
of two opposing connexon hemichannels; each a six connexin heaxamer. 
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 Figure.1.2 Connexins have four transmembrane domains and two extracellular 
loops which are well conserved. The C terminal and cytoplasmic loop domains are 
targets for post-translational modification. 
1.4 Gap Junction Lifecycle 
Connexin proteins are synthesized and trafficked by the secretory pathway: they 
are first synthesized by ribosomes on the rough endoplamic reticulum (ER) before 
being co-translationally inserted into the ER membrane, then trafficked in vesicles 
to the golgi apparatus via the trans-golgi network32. The particular connexin 
isoform determines where they oligomerize with other connexins to form 
connexons; some are formed in the ER and others in the golgi apparatus. 
Following oligomerization, connexons are transported to the cellular membrane 
in transport vesicles assisted by microtubules where they become membrane-
bound, and are available as hemi-channels to form gap junctions with adjoining 
cells33. Once inserted into the cell membrane, gap junctions congregate into 
groups of hundreds or thousands of channels by migrating laterally into clusters 
called plaques34. Plaques are maintained beyond the lifecycle of single connexons 
by the introduction of new connexons to the outside edge the plaque. Conversely, 
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the recycling of older gap junctions occurs from within the middle of the plaque. 
The addition of new connexons to the periphery and removal from the centre 
enables gap junction stability. Removal of gap junctions occurs by endocytosis of 
entire sections of the gap junction plaques by one of the two connected cells35,32. 
Degradation of these connexosomes is by both proteosome and lysosome 
pathways.36 
 
1.5 Regulation 
A number of factor influence the regulation of gap junction channel gating; 
transjunctional voltage (i.e., the difference in voltage between two connected 
cells), increases in Ca2+ levels, pH, and phosphorylation3,37 
1.5.1 Voltage 
Large voltages will induce the closure of gap junction channels, although the level 
required is variable depending on the isoform of the connexins involved. Gap 
junctions are maximally open when the transjunctional voltage is at 0mV, and 
begin to close as the transjunctional voltage changes either negatively or 
positively38. An example of this is Cx36 found in the brain, which at 100mV, has 
ten times the half-maximal inactivation voltage than the most sensitive connexin; 
Cx45, found in Purkinje fibres of the heart, at 10mV39’40. 
The sensor responsible for detecting these changes in connexin transjunctional 
voltage has been found to be located at the N- terminals which are situated at the 
pore entrance of connexons41. Amino acid residues on the N-terminal domain 
have been shown to be either positively or negatively charged, and when these 
amino acids are altered experimentally, the polarity of the gating is affected38. It is 
hypothesized that the N terminals are flexible and stabilized by hydrogen bonds 
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forming a funnel to open the channel, and then migrate across the channel and 
form a plug to close the channel42. 
1.5.2 Calcium 
It is thought that the closure and uncoupling of gap junction channels in response 
to intracellular Ca2+ functions as a way to protect healthy cells. Increased Ca2+ 
occurs as a result of the malfunction or breakdown of cells, therefore isolating 
these cells prevents healthy cells from becoming affected3. Experiments illustrating 
the effect of Ca2+ on gap junctions were performed by injections of large 
concentrations of Ca2+ into the cytoplasm of gap junction joined cells, which 
induced uncoupling43. Ca2+ itself may not directly act upon connexins, rather the 
protein calmodulin (CaM) could be the intermediary molecule responsible for the 
inhibitory effects3. CaM has been shown to bind to various parts of the 
cytoplasmic structure of connexins depending on the isoform. In Cx36, CaM 
binds to the c-terminal in response to increased Ca2+44, whereas it binds to the 
cytoplasmic loop in Cx4345. The involvement of CaM has been further confirmed 
by studies using blockers such as calmidazolium which prevented the Ca2+ 
induced uncoupling of cells, and even increased coupling46. CaM is thought to 
function by physically blocking the pore and thereby closing the channel. 
1.5.3 pH 
Decreasing the intracellular level of pH causes a closure of gap junctions. pH 
sensitivity to acidification is highly sensitive but variable, depending on the 
connexin isoform involved. Confounding this is conflicting data in neuronal Cx36 
channels which may be unique to Cx36 alone. Studies showed gap junction 
closure with decreased pH47, but others later found Cx36 uncoupling as a result of 
alkalinisation which normally increases coupling in other connexin channels. It 
has been proposed that Cx36 channels are different in that they may have both 
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acidification and alkalinisation gating mechanisms48. Because some connexins can 
be highly specific in their expression, certain tissues will be more susceptible to 
intracellular acidification. In contrast, extracellular acidification appears to have 
no effect on gap junction communication49. Despite this, open uncoupled 
connexin hemichannels respond to low extracellular pH by closing, however this 
is likely to occur when H+ ions enter through the hemichannel and close the 
channel from within the cytoplasm by binding to the same internal site as in 
formed gap junctions50. Causes of acidification can be due to glycolysis and 
phosphorylation, and as a result of anaerobic energy production. Unlike gap 
junction regulation by Ca2+, it is likely that H+ ions react directly with connexins. 
This is expected as the uncoupling of gap junctions and closure of uncoupled 
connexon hemichannels has been shown to be instantaneous when acidification 
was induced by CO251. Protonation of Cx43 was seen by Beahm and Hall, which 
highlights the ability of connexins to react directly with H+ ions without the use of 
an intermediary compound, unlike Ca2+ gap junction regulation50. The location 
of the connexin responsible for pH regulation is the C-terminal and the 
intracellular loop. Further to this, elimination of the C-terminal of Cx43 resulted 
in a complete lack of sensitivity to acidification, leaving the channel open52. 
Finally, other compounds with the ability to bind to the same location have been 
shown to partially inhibit pH induced uncoupling53. This direct binding may alter 
binding of the C terminal to the cytoplasmic loop to act as a ‘ball and chain’ where 
the C terminal; the ball, obstructs the pore channel. Interestingly, coexpression of 
CX43 and Cx40 in heterotypic gap junctions of Xenopus oocytes shows an 
elevated sensitivity to lowered pH than either Cx43 or Cx40 alone54. 
1.5.4 Phosphorylation 
Phosphorylation is crucial to a number of regulatory mechanisms: connexin 
synthesis, connexon assembly, trafficking, membrane insertion and gating 
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activity55. During connexon oligomerization and trafficking to the cell membrane, 
phosphorylation ensures the hemichannels remain in a closed state until they are 
activated as hemichannels or coupled as gap junctions56. Gap junction 
communication is affected when phosphorylation alters both the opening and 
closing of gap junctions55. A number of protein kinases are implicated in post-
translational modification of connexins, including serine/threonine-specific 
protein kinases such as; protein kinase C (PKC), cAMP-dependent protein kinase 
(PKA), Ca2+/calmodulin-dependent protein kinase II (CaMKII) and mitogen-
activated protein kinase (MAPK)57. The site of connexin phosphorylation is the C-
terminal as this domain contains a number of serine and tyrosine residues 
available for phosphorylation, of which multiple serine residues are primarily 
targeted. The C terminal location has been determined by sequence scanning, 
although the cytoplasmic loop is also a target for connexins Cx26, Cx56 and 
Cx3658,59,60. Cx26 is the only known connexin without C terminal phosphorylation 
sites as unlike all other connexins; it is not a phosphoprotein61. No 
phosphorylation of the N terminal has been found thus far in any connexin. Due 
to the variability in the C terminal of specific connexin isoforms, phosphorylation 
differentially regulates gap junction functionality depending on their constitution. 
 
 
1.6 Cx36 
Of all connexins discovered, Cx36 is the predominant connexin found in the 
mammalian central nervous system. It was initially discovered in 1998 as an 
ortholog to Cx35, which was previously found expressed in the retinal gap 
junctions of skate62. Cx36 is ubiquitously expressed throughout the CNS; in the 
hippocampus, cerebellum, thalamus, amygdala, ventral tegmental area, and 
nucleus accumbens along with others63,. Being a part of numerous regions 
responsible for many functions shows the importance of Cx36 to a large range of 
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neuronal mechanisms. The hippocampus is important in memory and learning 
processes, and the presence of Cx36 suggest a vital role in these as experiments on 
Cx36 knockout mice have demonstrated impairment in both memory and 
learning64. CX36 is expressed in neuroendocrine cells of the hypothalamus that 
produce hormones such as oxytocin (OT), vasopressin (VP), gonadotropin 
releasing hormone (GnRH), corticotrophin  releasing hormone (CRH) and 
growth hormone releasing hormone (GHRH)65. Due to the wide-ranging effects 
and systems these hormones control and interact with, it is reasonable to presume 
that Cx36 is likely to be implicated in many of these, however research into the 
role of Cx36 in the hypothalamus is currently limited. 
The temporal expression of Cx36 illustrates a role in the development of the CNS. 
In mice, Cx36 is first expressed in the mouse embryo forebrain at 9.5 days which is 
the beginning of neurogenesis. The peak occurs at the second postnatal week 
which is thought to correspond with early environmental stimuli. From this point 
expression decreases until it reaches the lower levels seen in the adult brain66. 
 
1.7 Cx36 Structure  
Cx36 has a 321 amino acid sequence, and contains the intracellular loop; 
identified as the site for the majority of regulatory interaction, which is a 99 amino 
acid chain containing a glycine rich sequence of 18 amino acids.  
The Cx36 or gap junction delta-2 protein (GJD2) gene is highly conserved across 
identified species, where the human Cx36 gene is 98% identical to both the mouse 
and rat Cx36 gene. Interestingly this is also 80% identical to the skate and 83% 
identical to perch Cx3567.  In the Cx35/Cx36 connexin group, the gene is 
constructed of two exons separated by a 1.05 kb intron that begins in the coding 
region 71 bp after the initial translation site. Most other connexin genes in 
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comparison consist of an intron in an untranslated region, with the entire 
uninterrupted coding sequence in a single exon68. In mice the gene has been 
mapped to chromosome 2F3 which shows homology to 15q14, which is where the 
location has been mapped in human Cx36.69 
Cx36 is exclusively assembled into homomeric connexons, and dock with 
identical connexons on adjacent cells to form homotypic gap junctions22. This 
exclusivity means that Cx36 gap junctions retain the same specific properties 
wherever they are expressed. Cx36 is only found in GABAergic interneurons, and 
no other connexin isotype has been found in GABAergic interneurons70. Voltage 
sensitivity and single channel conductance are both extremely low in comparison 
to other connexins, which may have the benefit of the channel remaining in the 
open state over a larger range of neuronal activity. 
  
1.8 Cx36 and eating behaviour 
The role of the reward system in the consumption of palatable foods has been 
most shown in studies linking obesity and food addiction to the same neural 
pathways as other more established substance based addictions71,72,73. It is these 
same brain regions and pathways in which Cx36 may play a crucial role. 
The reward system of the brain evolved as a mechanism to enhance survival and 
reproduction. Behaviours that are needed for this such as eating, drinking and sex, 
stimulate the reward regions resulting in subjective feelings of wellbeing. The 
behaviour becomes associated with these feelings, acting as a reinforcer, thereby 
ensuring its future repetition74. 
Anatomical structures of the mesolimbic pathway of the reward system are the 
prefrontal cortex, amygdala, and most importantly the ventral tegmental area 
(VTA) and nucleus accumbens (NAc) which are the main reward centres75. The 
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primary mediator of this pathway is dopamine (DA). The VTA sends 
dopaminergic projections to the NAc, which release DA into the NAc and is 
responsible for feelings of wellbeing76,77. GABAergic neurons of the VTA however, 
act as inhibitors of dopaminergic neurons, controlling the amount of DA released 
in the NAc78. 
Exogenous drugs responsible for addiction hijack the reward system, often 
stimulating it to a degree far beyond that of the natural stimuli it evolved to 
respond to. Addictive drugs do not all act in the same way, but ultimately they all 
increase the amount of DA in the NAc79. An example of this is cocaine, which 
prevents reuptake of dopamine in the synaptic cleft of dopaminergic neurons, 
leaving more DA circulating in the synaptic cleft80. Another example is opiate 
based drugs. These bind to natural opiate receptors and are believed to act on 
GABAergic neurons in the VTA, preventing their inhibitory effects on DA release 
into the NAc by dopaminergic neurons, again resulting in increased DA in the 
NAc81. 
The intake of palatable food is mediated by the mesolimbic dopamine pathway, 
and even natural palatable stimuli can cause abnormal regulation as in the case of 
food addiction and its physical manifestation, obesity82. Pleasure derived from 
palatable food is normal and does not indicate dysregulation, as food intake is 
controlled by a number of other systems. Hunger and satiety signals controlling 
energy balance interact with the reward system by respectively inducing neuronal 
response to food during hunger, and reducing the response as a result of satiety83. 
There is a complex interplay between neural and neuroendocrine regulators of 
metabolism initiated in the periphery to maintain energy and bodyweight 
homeostasis84. These signals are integrated within various regions of the 
hypothalamus such as the arcuate nucleus. Examples of these regulatory 
compounds are Ghrelin; a major orexigenic hormone released by the anterior 
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pituitary which increases the motivation to eat, and leptin; a peptide released by 
adipose tissue which initiates feeding termination. Leptin acts on the 
hypothalamus and directly on VTA dopaminergic neurons reducing the reward 
value of palatable foods85. Rats administered ghrelin had an increased activation of 
the reward system, enhancing the hedonic value of platable food86. Conversely, 
leptin directly injected into the VTA caused inhibition of DA, consequently 
reducing food intake85. 
As with increased duration of reward-stimulating drug administration, long-term 
consumption of highly palatable foods results in a decreased responsiveness by the 
reward system. This tolerance is a compensation of the brain to attempt to regain 
homeostasis; however, the decreased reward can further motivate 
overconsumption in an effort to avoid the negative effects of reward withdrawal87. 
The consumption of alcohol increases dopamine levels via both directly exciting 
VTA dopaminergic neurons projecting to the NAc88, and indirectly; by inhibiting 
GABAergic neurons that inhibit dopamine release89. Some of the strongest 
evidence implicating Cx36 gap junctions in the mediation of reward has been 
studies comparing the impact of alcohol administration to Cx36 knockout (KO) 
and wild-type (WT) mice. KO mice drank significantly less alcohol than WT, and 
additionally, WT mice treated with the CX36 antagonist mefloquine also drank 
less than untreated WT mice90. It was concluded that CX36 gap junction 
uncoupling between VTA GABAergic neurons allowed increased DA neuron 
firing, and a permanent increase in NAc dopamine. Considering alcohol was no 
longer as rewarding when Cx36 was either absent or blocked, it is hypothesized 
that it is via Cx36 gap junction electrical synapses that VTA GABAergic neurons 
communicate to regulate DA synthesis in the NAc.  
Aversive response is at the opposing end of the same continuum as reward, 
therefore many of the same brain regions, pathways and peripheral mechanisms 
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are involved in each. A conditioned taste aversion (CTA) is a phenomenon that 
occurs when a novel tastant is temporally associated with malaise, resulting in the 
novel food being avoided upon future presentation to protect against repeated 
illness. These can be created experimentally by pairing a rewarding novel food 
with a toxic stimulus. The aversion is thereafter elicited in order to avoid the toxic 
tastant.  
Considering the effect of Cx36 on rewarding substances, its anatomical location in 
the mesolimbic system, the neural and neuroendocrine effect of food and other 
rewarding stimuli which ultimately guide reward seeking behaviour; it is 
presumed that Cx36 will be linked to the intake of food driven by the reward 
system. However, Cx36 is not only implicated in reward mechanisms, but it is also 
located in some of the pivotal regions governing metabolic neural and endocrine 
mechanisms, potentially linking Cx36 to non-reward related regulation of food 
intake. 
 
1.9 Aims 
In contrast to studies investigating the metabolic mechanisms driving feeding 
intake dysregulation, the role of the reward system will also be researched. Normal 
energy balance homeostasis can be overridden in eating disorders such as obesity, 
where food intake is determined by the reward received by palatable foods rather 
than feelings of hunger and satiety. The purpose of these studies is to find 
pathways controlling the ingestive response to palatable foods to further elucidate 
pathways by which we can control this response with the goal of reducing obesity.  
The first specific aim we will look at is whether Cx36 has a role in the intake of 
palatable foods. We will test this by determining whether the KO of Cx36 has an 
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effect on sweet palatable food consumption in both short-term and long-term 
exposures.  
Next we will investigate whether Cx36 plays a role in aversion to palatable foods. 
This will be examined by testing whether the knockout of Cx36 affects acquisition 
of a conditioned taste aversion to a novel sweet palatable tastant. 
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2 
2. Effect of Cx36 knockout on the 
consumption of rewarding tastants 
 
Abstract  
Food intake is controlled by both hedonic and postingestive mechanisms. The 
reward system is activated by consumption of sweet palatable foods, which are 
associated with pleasure, and thus drive consumption. Knockout (KO) of 
Connexin 36 (Cx36) gap junctions has recently been linked to disruption of 
sensitivity to rewarding stimuli; therefore it is proposed that connexin 36 may be 
crucial to reward response to sweet foods. Short-term and long-term feeding 
paradigms examining a number of sweet palatable tastants illustrated that deletion 
of Cx36 decreases sweet tastant consumption. Additionally, concurrent 
consumption of sweet tastants and bland chow increased chow intake. Current 
data suggest Cx36 is a component of feeding for reward.  
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2.1 Introduction 
2.1.1 Regulation of food intake 
Food intake controls are broadly separated into two mechanisms: postingestive 
regulation, and hedonic regulation which is responsible for the derivation of 
pleasure from the taste of palatable foods. The integration of these systems firstly 
in the hypothalamus culminates to enable energy balance and body weight 
homeostasis despite fluctuating changes in caloric ingestion and energy intake1. 
2.1.2 Postingestive regulation of food intake 
Postingestive mechanisms respond to the caloric, macronutrient content, and 
volume of food, and act to mediate food intake by inducing hunger or satiety 
signals. Peripheral satiety is determined primarily by mechanical and endocrine 
responses to food intake2,3. Distension of the gastrointestinal wall in response to 
ingestive load engages mechanoreceptors which sense stretch and volume, 
relaying this information via vagus afferent signals to the brain, triggering satiety 
pathways and terminating feeding behaviour4. 
Energy balance and adiposity is signalled by leptin produced in adipocytes and 
gastric epithelial cells. It is thought that adipocyte synthesized leptin influences 
long-term food intake, and gastric secretion influences short-term intake in 
response to immediate local response to ingested food5. Leptin induces satiety 
centrally by releasing a number of peptides known to be anorexigenic such as 
alpha-melanocyte stimulating hormone (a-MSH), suppressing the orexigenic 
agouti-related protein (AGRP) and working synergistically with cholescystokinin 
(CCK) to inhibit hunger6,7. 
Ghrelin is the major hormone known to induce hunger, and is synthesized in the 
stomach and small intestine. Increases in ghrelin are anticipatory and surge before 
26 
 
meals, before decreasing again after consumption of caloric macronutrients8, most 
strongly in response to carbohydrate consumption followed protein and fat. 
Central targets are neuropeptide Y (NPY) and AGRP neurons in the arcuate 
nucleus of the hypothalamus9. Long-term control of food intake is also influenced 
by ghrelin, and is due to the inverse relationship between ghrelin and bodyweight. 
An increase in hunger coincides with the loss of bodyweight in an attempt to 
maintain homeostasis10.  
2.1.3 Sweet taste and reward 
Intake of sweet palatable foods can be induced independent of hunger and satiety 
mechanisms; this is by association of sweet taste to pleasure controlled by the 
reward system of the brain11. The mesolimbic dopamine system is the main focus 
in the study of the reward system, and it is this pathway which is also vital for the 
acquisition and maintenance of addictions, both behavioural and substance 
based12,13. In the presence of a food addiction, the normal homeostatic nature of 
food intake is suppressed, causing continued feeding behaviour even in the 
presence of satiety signalling14. Brain areas making up the mesolimbic DA 
pathway are the VTA and the NAc12. DA projections extend from the VTA to the 
NAc where an increase in DA induces pleasure, reinforcing the associated 
behaviour15,16. A preference for sweet taste is innate17, and has most likely been 
evolutionarily selected for as increased consumption of sweet foods due to reward-
seeking behaviour would have enhanced the chances of survival and reproductive 
success. A preference for sweet tastants has been shown for sugars and synthetic 
sweeteners18; but in studies of sweet taste indifferent mice, a preference over water 
was only shown by caloric sweet tastants19, indicating the reward system may be 
activated by caloric sweet tastants in the mouth and also in the gastrointestinal 
tract. It is therefore apparent that non caloric sweet tastants only activate the 
reward system by oral sweet taste receptors. 
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2.1.4 Cx36 mediated reward  
Gap junction channel protein Cx36 knockout (KO) mice have a decreased self-
administered intake of alcohol in comparison to WT mice20. The expression of 
Cx36 in the VTA and NAc, and the alcohol intake reduction when Cx36 is 
genetically deleted in KO mice suggests Cx36 as a vital component of reward 
pathways. 
A recent as yet unpublished study led by Dr Pawel Olszewski of the University of 
Waikato, New Zealand21, has illustrated a decrease in consumption of sweet 
palatable tastants in Cx36 KO mice compared to their wild-type counterparts. All 
sweet tastants in this research were affected, with caloric sweeteners most 
profoundly so. Additionally, consumption of water was unaffected by the deletion 
of Cx36. 
The aim of these experiments is to confirm recent investigations showing that 
Cx36 is implicated in the reward mediated consumption of sweet palatable 
tastants, and whether this effect extends to female mice. 
 
2.2 Materials and Methods 
2.2.1 Animals 
Adult female WT and Cx36 KO mice were housed in individual cages in a 
temperature controlled room at 22°C on a 12:12 light dark cycle (light begins at 
0600h). The mice weighed approximately 27g at the start of the experiment. Prior 
to the experiment mice had access to ad-libitum tap-water and bland chow 
(Teklad). Cx36 KO mice were originally created by Dr David Paul (Harvard 
Medical School, USA)22, and our colony was generated using standard breeding 
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methodology as described therein. The procedures described herein were granted 
approval by the University of Waikato animal ethics committee.  
 
2.2.2 Experiment 1. Food, palatable tastant and caloric consumption 
Mice were fed chow pellets and water ad-libitum prior to the start of the 
experiment unless otherwise stated. Over a period of 4 days, mice (n=26 KO, 14 
WT) were given chow and a sweet tastant solution ad-libitum. The liquid tastant 
solutions were tested sequentially (water, saccharin 0.1%, sucrose 10%, glucose 
10%, fructose 10%), with each beginning at the start of a new week. Both chow 
and water were measured after each 24hr period, and spillage was accounted for. 
The mice were weighed at the same time as chow and sweet tastant each day 
(1100h), and daily consumption was calculated by gram of bodyweight. The effect 
of Cx36 on chow and sweet tastant intake was determined using t-tests. P values 
were considered significant when P <0.05. 
 
2.2.3 Experiment 2. Short-term palatable tastant consumption 
A new set of adult female mice weighing approximately 24g were used to 
determine the effects of the same tastants used in Experiment 1 over a short-term 
exposure. Mice (n = 11 KO, 11-13 WT) were fed chow and tapwater ad-libitum 
unless otherwise stated. For 5 days mice were given 2 hour access to a sweet liquid 
tastant per day (1100h – 1300h), with chow and water removed; the remainder of 
each 24hr period mice had ad-libitum access to chow and water. The tastants 
(saccharin 0.1%, sucrose 10%, glucose 10%, fructose 10%) were tested sequentially, 
each beginning at the start of a new week. Mice began drinking immediately upon 
presentation of liquid tastants. Bottles were weighed and corrected for spillage at 
the start and end of each 2h test. The volume of liquid consumed was calculated 
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and recorded as ml/g of bodyweight. T-tests were performed to determine 
whether knockout of Cx36 affected the short-term consumption of sweet tastants. 
P values were considered significant when P ≤ 0.05. 
 
2.3 Results  
2.3.1 Experiment 1. Food, palatable tastant and caloric consumption 
Concurrent ad-libitum exposure to bland chow, palatable caloric and non-caloric 
fluids in Cx36 KO female mice is associated with overconsumption of bland chow 
and decreased intake of palatable fluids (Fig. 2.1). Consumption of all sweet 
tastants was decreased in Cx36 KO mice, with intake of saccharin, sucrose and 
most notably glucose significantly decreased. Fructose consumption showed a 
trend towards decreased intake, however did not reach the level considered 
significant. Total caloric intake increased in Cx36 KO mice when chow was 
presented with non-caloric liquids, and decreased when chow was presented in 
conjunction with sucrose and glucose. Concurrent chow and fructose 
consumption resulted in no change in caloric intake. 
 
2.3.2 Experiment 2. Short-term palatable tastant consumption 
Palatable tastants-only short-term exposure is associated with the reduction of 
glucose and sucrose solution intake in Cx36 KO mice, thus, the tastants that were 
most profoundly affected in Experiment 1 (Fig. 2.2). While fructose consumption 
showed a decreased yet insignificant intake during 24h concurrent exposure with 
chow in Experiment 1, it was unaffected during short-term palatable tastant 
exposure.  
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 Figure 2.1 Chow and palatable tastant intake was determined during 24 hour 
concurrent administration comparing Cx36 KO and WT mice. A Cx36 KO 
increases consumption of chow administered with all liquids. B Consumption of 
sucrose, glucose and fructose is decreased by Cx36 KO. C Total caloric intake of 
concurrent liquid and chow administration is decreased with sucrose and glucose, 
and increased with non-caloric liquids. (*- P ≤ 0.05, ** -P ≤ 0.01 *** - P ≤ 0.001). 
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 Figure 2.2  Knockout of Cx36 in female mice decreases consumption of glucose 
and sucrose during short-term exposure. Palatable tastant intake was measured 
after 2 hours of administration. (*- P ≤ 0.05, ** -P ≤ 0.01 *** - P ≤ 0.001). 
 
2.4 Discussion 
When looking at the mechanisms regulating food intake, we can determine that 
the reward system plays a major role1. Dysregulation of the reward system can 
result in a loss of homeostatic control which regulates bodyweight by integrating 
hunger and satiety signals with pleasure and motivation14. A preference for sweet 
tasting food is evident in a range of human and other mammalian studies. Its 
intake activates the reward system, becoming associated with pleasure, and thus 
increases sweet food seeking behaviour11. Cx36 is found throughout brain regions 
implicated in appetite and reward, and has recently been demonstrated to alter 
intake of rewarding substances20,21, therefore it is speculated Cx36 is also involved 
in sweet taste induced feeding reward. 
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The results of Cx36 deletion on long-term food intake show a decrease in the 
consumption of palatable sweet tastants. This suggests that Cx36 is a crucial 
component of reward mediated sweet taste signalling. Major reward regions of the 
brain show expression of Cx36, implicating this connexin in reward pathways23. 
Previous research studying the effect of Cx36 deletion on reward mediated alcohol 
consumption suggests CX36 gap junction channels enable the communication of 
adjacent VTA neurons, the abolishment of which interrupt DA release in the 
NAc20. The mechanism inducing alcohol reward is highly correlated with that of 
sweet taste reward. Thus, it is likely the decrease in sweet tastant consumption is 
the result of diminished cell-to-cell communication in the VTA and NAc. 
Supporting the hypothesis that sweet taste is specifically affected and the response 
is not merely the feeding termination of all foods is the change in bland chow 
consumption when administered together with sweet tastants. In contrast to sweet 
tastants, Cx36 deletion increases chow consumption. This also suggests that 
various peripheral postingestive regulatory processes respond to a decrease in 
reward induced consumption, possibly by increasing consumption of chow to 
maintain homeostasis. Cx36 has been found in pancreatic islet β-cells, whose 
coupling is important for insulin secretion in response to glucose. While loss of β-
cell Cx36 channels prevents glucose induced insulin release, basal insulin secretion 
is increased, as illustrated by Cx36 deletion24. This is equivalent to the function of 
β-cells in type 2 diabetes. Similarly, a high fat diet was fed to C57BL/6 mice that 
later became pre-diabetic and obese as measured by glucose sensitivity and insulin 
resistance. Pre-diabetic mice were shown to have a significantly decreased level of 
Cx36 gap junctions than control mice25. A close relationship is therefore defined 
between Cx36 and diabetes, as loss of Cx36 induces insulin response typical of 
type 2 diabetes, and a pre-diabetic condition reduces Cx36 gap junctions. For this 
reason, an impaired insulin response is possibly a causative factor in sugar 
consumption of Cx36 vs. WT mice. 
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When accounting for both the decrease in sweet tastants and increase of chow, 
there remains a net decrease in total caloric intake, excluding non-caloric water 
and saccharin tests. Results for long-term exposure mirrored that of the previous 
study where male Cx36 KO mice consumed less sweet tastants21, confirming that 
the effects are not gender specific. Short-term exposure to sweet palatable tastants 
consequently produced similar results to long-term exposure. The only noticeable 
change was a shift from a non-significant trend in Cx36 KO fructose 
consumption, to no difference during the short-term exposure.  In both long and 
short-term paradigms, Cx36 KO mice ingested similar amounts of all sweet 
tastants; therefore it is in WT mice that differences in sweet tastant consumption 
are evident. Rodents display differing preferences to various sugars which may 
account for the consumption differences in WT mice26,27. 
The reward system is comprised of a number of brain regions which also interact 
with appetite regulatory pathways1. These studies have illustrated that Cx36 
participates in the regulation of feeding for reward. The increased consumption of 
chow is also suggestive of Cx36 involvement in metabolic processes in addition to 
reward processes. Further research should investigate which specific brain regions 
are affected by Cx36 during food intake. Immunohistochemical studies could now 
be undertaken where target antigens, such as the transcription factor protein c-Fos 
which is a marker of recent neuronal activity, are targeted by specific antibodies 
and stained to visualize regions of activity that may be involved in a particular 
mechanism28.  
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3 
3. The effect of Cx36 knockout on a 
conditioned taste aversion 
Abstract  
Associating a malaise inducing stimuli to a novel food by classical conditioning 
creates a conditioned taste aversion (CTA) to the novel food. Aversion and reward 
processes are on opposite ends of the same continuum, though it is uncertain 
whether Cx36 gap junctions implicated in reward are also essential to a CTA. It 
was therefore proposed that knockout (KO) of Cx36 would increase aversive 
sensitivity to a sweet novel tastant in mice during a CTA reward paradigm. During 
a two bottle test of a sweet novel tastant vs. water, preference for a sweet tastant 
was decreased from 70% in wild-type (WT) mice to 27% in Cx36 KO mice when a 
LiCl was administered following sweet tastant consumption. Total liquid intake 
was unaffected by KO of Cx36 gap junctions. These results illustrate that Cx36 KO 
exaggerates the response of a LiCl induced CTA to a sweet novel tastant. 
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3.1 Introduction 
A conditioned taste aversion (CTA) is acquired when the effects of a toxin are 
associated with novel tasting food. It is a form of classical conditioning where an 
unconditioned stimulus: a malaise inducing toxin, is paired with a conditioned 
stimulus: novel tasting food1.  A novel stimulus is used because pre exposure may 
result in latent inhibition, preventing or diminishing the acquisition of a CTA2,3. 
CTAs are necessary to protect animals from poisoning. If the ingestion of a 
substance is followed by illness, an animal will avoid the suspected harmful 
substance to prevent further illness4. The association between the toxin and the 
novel food is long-lasting and results in future avoidance of the novel food when it 
is later presented5,6. One of the most used chemicals to cause gastrointestinal 
discomfort in experimental settings is lithium chloride (LiCl), which is highly 
effective at decreasing food consumption7.  
A range of processes are integrated to establish a CTA. Reward, fear learning, 
memory and peripheral postingestive mechanisms are all required for the 
acquisition and retrieval of CTAs8,9,10. Creating a CTA to sweet palatable tastants 
shifts the response from reward to aversiveness despite the tastant being 
intrinsically unchanged. The hedonic shift from positive to negative illustrates the 
proposition that reward and aversion are mechanisms at opposing ends of the 
same continuum. Reinforcing this view is evidence showing that brain regions in 
the reward system are also activated during acquisition and retrieval of a CTA, 
specifically the amygdala, the ventral palladium (VP), ventral tegmental area 
(VTA) and nucleus accumbens (NAc)11,12.  
Neuroendocrine studies in taste aversion also implicate oxytocin (OT), opioids, 
and dopamine (DA) in the mesolimbic reward pathway13. Pairing a sweet palatable 
solution with an aversive stimulus has the reverse effect on the VTA to NAc 
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pathway that the same sweet palatable has sans aversive stimuli. NAc DA is 
suppressed to a similar level as during bitter taste consumption14.  
OT is a satiety regulator, initiating termination of feeding, particularly associated 
with carbohydrate consumption15,16. Numerous studies have shown that deletion 
of the OT gene enhances consumption of sweet solutions, but leaves lipid based 
solution consumption unchanged16,17. In contrast, opioids increase consumption 
of palatable foods irrespective of caloric content, even in the presence of satiation, 
implicating the reward pathway18.  Opioid agonists attenuate aversive response to 
LiCl, whereas blocking opioid receptors with the opioid receptor antagonists 
naltrexone and naloxone heighten the aversive response19,20. A relationship 
between opioids and OT cells in the paraventricular nucleus (PVN) and 
supraoptic nucleus (SON) of the hypothalamus is apparent in the regulation of 
taste aversion. OT is released in these areas after injection of LiCl, and when 
various opioids are administered prior to LiCl, the LiCl induced CTA is 
attenuated as evidenced by decreased c-Fos expression in the PVN13. These same 
hypothalamic regions also express Cx36 which potentially links a CTA to Cx36 via 
the hypothalamus. 
Taking into account the effect of Cx36 gap junctions on reward mediated sweet 
tastant intake as illustrated in chapter 1, and the evidence linking CTA to the same 
reward pathways, it is hypothesized that Cx36 mediated communication is crucial 
to reward related pathways therefore its deletion will alter aversive response. 
Hypothalamus regions mediating aversiveness also express Cx36 which may also 
affect aversive response by non-reward related mechanisms.  
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3.2 Materials and Methods 
3.2.1 Animals 
Adult male WT and Cx36 KO mice were housed in individual cages in a 
temperature controlled room at 22°C on a 12:12 light dark cycle (light on at 
0600h). Mice weighed ~30g prior to the experiment and had access to ad-libitum 
tap-water and bland rodent chow (Teklad). Cx36 KO mice were originally created 
by Dr David Paul (Harvard Medical School, USA)21, and our colony was generated 
using standard breeding methodology as described therein. The procedures 
described herein were granted approval by the University of Waikato animal 
ethics committee 
 
3.2.2 Conditioned taste aversion 
Mice were fed bland chow pellets and water ad-libitum for 5 days prior to the start 
of the experiment. For 2 days mice were then acclimatised to deprivation of chow 
and water for 5 hours (1300 – 1800h) to ensure hunger and thirst, with chow and 
water replaced immediately prior to the beginning of the 12h dark cycle. On day 3, 
a sweet novel tastant (pineapple juice, Golden Circle) was then administered for 
1hour post deprivation for 2 hours (1800h – 2000h). WT and KO mice were each 
randomly divided into two groups (n=8 each): one group given intraperitoneal 
(IP) injections with 6 mEq/kg bw LiCl, and one group given IP saline solution 
injections. All injections were administered after 2hr of novel tastant 
consumption. Chow and water were replaced 30min after injections. All mice had 
24 hour ad-libitum access to water and chow on day 4 to allow recovery from the 
effects of LiCl. On day 5 mice were deprived of food and water for 5 hours (1300h 
– 1800h), before being administered a 2-bottle test to assess acquisition of a CTA 
to the novel tastant. The bottles were weighed and corrected for spillage to 
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ascertain consumption. The amount of novel tastant consumed in ml/g of 
bodyweight and the percentage of total fluid intake were analysed using t-tests and 
were considered significant when P ≤ 0.05. 
 
3.3 Results 
In a two bottle test of water and a sweet novel tastant, Cx36 KO mice display 
increased sensitivity to aversive treatments: a threshold dose of LiCl (i.e., sufficient 
to induce a very mild CTA in WT mice) causes pronounced aversion in KO mice 
(Fig. 3.1). There was a trend towards decreased total liquid intake in Cx36 KO 
mice; however this did not reach significance. The CTA was shown in both WT 
and KO mice by the volume of novel tastant consumed, with the increase in 
aversiveness by KOs most evident in the percentage of novel tastant intake. WT 
consumed 70% of total liquid intake as sweet tastant while Cx36 KO mice 
consumed 27% as sweet tastant. 
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 Figure 3.1 Knockout of Cx36 in male mice increases the magnitude of aversive 
response during a LiCl induced CTA to a sweet novel tastant, but does not affect 
total liquid intake. A Novel tastant consumption as a percentage of total liquid 
intake. B Intake of individual liquids (ml/g bw) C Total liquid intake (ml/g bw). 
Novel tastant and water intakes were established during a standard two-bottle test 
(novel tastant vs. water) in female mice treated with either 6 mEq/kg bw. LiCl or 
saline.   (*- P ≤ 0.05, ** -P ≤ 0.01 *** - P ≤ 0.001). 
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3.4 Discussion 
Gap junction communication is ubiquitous throughout mammalian tissue and is 
as diverse functionally as it is distributionally22. Cx36 gap junctions have been 
illustrated to participate in reward related behaviour in response to a number of 
associated stimuli. Most recently the studies from chapter one demonstrate that 
lack of Cx36 decreases reward, possibly by diminishing the hedonic value of sweet 
palatable foods.  
A CTA, like reward, is a complex interaction of multiple brain regions and 
pathways where toxicity is associated to a previously neutral stimulus, reducing or 
eliminating its consumption1.  Some of these pathways are shared between reward 
and aversion11,12; when one mechanism is stimulated it causes an increase in 
reward response, conversely when that same mechanism is blocked it causes an 
increase in aversive response. If the subsequent proposition is true that both 
reward and aversion are opposites of the same spectrum, it is hypothesized that 
since Cx36 deletion decreases the reward related consumption of sweet foods, it 
will also increase aversive sensitivity to malaise associated foods. Despite some 
new research into Cx36 in the reward system, the relative recency of its discovery 
and broad range of functions and tissues in which it is expressed means that there 
is as yet limited knowledge as to its possible function in aversion. 
In a two bottle test of water vs. a sweet novel tastant, both Cx36 KO and WT mice 
had a decreased total liquid intake after LiCl induction of a CTA to the sweet 
tastant. There were no significant differences in total intake between KO and WT 
in either the LiCl or saline treated groups, suggesting Cx36 had no effect on thirst 
as a consequence of a CTA. 
The percentage of sweet novel tastant consumption between saline injected KO 
and WT was statistically insignificant, however, Cx36 KO mice consumed 27% 
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sweet tastant and WT consumed 70%. Differences in consumption of the sweet 
malaise-associated tastant only, and not in total liquid intake suggests Cx36 does 
in fact generate remarkably increased sensitivity to aversive stimuli as 
hypothesized. There was a diminished preference for the aversive conditioned 
sweet tastant while leaving total liquid intake unchanged suggesting there is an 
aspect of the reward system affected by knockout of Cx36.  
There are a number of mechanisms that Cx36 could act upon. Based on the results 
from feeding studies in chapter one, it is likely that the mesolimbic dopamine 
pathway within which Cx36 is found plays a role, but this may not be the only 
mechanism Cx36 acts upon. Previous research has found OT cells in the PVN and 
SON to mediate acquisition of a LiCl induced CTA. An alternative explanation for 
the enhanced aversive response to sweet tastants is that Cx36 found within these 
neuronal populations alters the endocrine mediated aspects of a CTA. 
A CTA is not the result of activation of a single pathway, nor is Cx36 expressed in 
a single pathway. Memory, fear learning, reward and postingestive endocrine 
regulation are all involved in acquisition of a CTA, and Cx36 is expressed 
throughout neurons of multiple CTA correlated brain regions. Elucidation of 
which parts of these processes Cx36 influences therefore requires investigation of 
these individually. I have found Cx36 is important in sweet tastant consumption 
and LiCl induced aversion to sweet tastants, but it is uncertain by which neuronal 
populations and neuroendocrine factors this occurs. That Cx36 is implicated is 
herein confirmed, how it is implicated needs to now be explored. 
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4 
4. Conclusions and Perspectives 
The results within this thesis have expanded the knowledge of connexin 36 (Cx36) 
as an important component in the regulation of consummatory behaviour.  There 
is currently limited research into Cx36 and consummatory behaviour; however, 
recent research has implicated Cx36 in consumption of alcohol1, and preliminary 
studies have linked CX36 knockout (KO) to diminished sweet solution 
consumption in male mice2. In my current experiments, Cx36 knockout (KO) was 
shown to decrease the consumption of sweet palatable tastants and increase 
consumption of bland chow compared to wild-type (WT) counterparts. Also 
shown is that during a conditioned taste aversion (CTA), Cx36 KO increases the 
aversive response to a sweet novel tastant.  
Cx36 KO and WT mice were exposed to sweet tastants, resulting in a decrease in 
consumption of sucrose and glucose during short term intake in KO mice, and 
decrease in consumption of saccharin, sucrose and glucose during long term 
intake. In addition to the decrease in sweet tastant intake was an increase in bland 
chow consumption when consumed concurrently. Knockout of Cx36 decreases 
intake of sweet foods, possibly by diminishing their hedonic value which suggests 
the necessity of Cx36 for the proper communication between neuronal cell 
populations within the reward system. However, an increase in bland chow  
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consumption by Cx36 KO mice is suggestive of homeostatic postingestive 
regulation responding to caloric content, macronutrient content and volume of 
gastric load. 
To test whether Cx36 affects acquisition of a CTA, a novel sweet tastant was 
administered immediately prior to injection of LiCl to create a CTA to the sweet 
tastant. Malaise caused by the LiCl was consequently associated with the sweet 
tastant, decreasing its consumption. A mild aversion was acquired by WT mice, 
but Cx36 KO mice showed significantly increased aversive responsiveness to the 
sweet tastant.  
That reward and aversion are opposing on the same continuum is thereby 
supported by the results of the CTA when combined with the rewarding sweet 
tastant consumption results. It was predicted that Cx36 would be involved in the 
consumption of rewarding foods, altering their intake, but the results may now 
also implicate Cx36 in postingestive mechanisms of consummatory behaviour. It 
is unclear whether Cx36 is a component of these mechanisms inducing bland food 
intake, or if this increased intake is merely a homeostatic response to a decreased 
gastric volume and caloric intake. 
The implication of Cx36 in feeding reward opens the possibility of manipulation 
to treat eating disorders such as obesity, or related diseases including diabetes; as 
Cx36 is a component of insulin secretory mechanisms2,3. Investigations could 
begin with genome wide association studies to indentify whether any single 
nucleotide polymorphisms in the Cx36 GJD2 gene are associated with obesity or 
other eating disorders4,5,. If there is associated genetic variation in GJD2 it may be 
possible to develop pharmacological interventions. Selective blockade of Cx36 
channels by the creation of synthetic ligands may consequently modify appetite 
which is disrupted in eating disorders. Further to this, the results from the current 
studies of food intake and those associated with alcohol consumption suggest  
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CX36 may be associated with the wider phenomenon of addiction. Modulation of 
Cx36 could treat a variety of addictions both behavioural and substance based. In 
the case of addictive-like overeating, which has neurobiological similarities to 
substance addiction6,7, the health implications of obesity could be mitigated by 
decreasing the underlying hedonic value of palatable foods that drives excessive 
consumption.  Current pharmaceuticals used to treat  addictive-like conditions 
show some efficacy8,9, however, drugs with higher specificity and efficacy could be 
produced. 
In these studies I have investigated the role of Cx36 in consummatory behaviour, 
and have found that Cx36 KO diminishes intake of sweet tastants and increases 
intake of bland chow during concurrent consumption.  Furthermore, a LiCl 
induced CTA is enhanced by KO of Cx36. 
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